异常的BCAT1表达增加了MTOR活性,加速了慢性淋巴细胞白血病的疾病进展
Qiangqiang Shao1, Jedrzej Wykretowicz1, Nan Hu1
1Departments of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Leukemia
|October 25, 2024
概括
慢性淋巴细胞白血病 (CLL) 中分支链氨基酸转移酶1 (BCAT1) 的异常表达与生存率低下和Venetoclax敏感性降低有关. 在CLL中,BCAT1可能代表了一个新的治疗点.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是一种异质的B细胞恶性瘤.
- 特定的遗传异常,如del17p/TP53mut和三发症12,与不同的临床结果有关.
- 代谢重编程越来越被认为是癌症的标志,包括CLL.
研究的目的:
- 研究CLL中代谢酶分支链氨基酸转移酶1 (BCAT1) 的作用.
- 确定BCAT1表达与CLL中的特定遗传亚型和临床参数的关联.
- 探索BCAT1在CLL病变和治疗反应中的功能和临床影响.
主要方法:
- 从117个流量排序的CLL样本中分析mRNA/cDNA的基因表达概况.
- 使用免疫组织化学或其他方法验证BCAT1表达.
- 通过p-S6K水平测量mTOR活动.
- 稳定状态代谢学和重同位素代谢追踪.
- 在BCAT1受损细胞系和初级CLL细胞中评估Venetoclax敏感性和细胞生长.
主要成果:
- 在CLL中检测到异常的BCAT1表达,特别是在del17p/TP53mut (66%) 和三发症12 (77%) 的病例中,并且在正常B细胞中不存在.
- BCAT1表达与CLL细胞中增加的mTOR活性和改变的BCAA代谢相关.
- 具有高BCAT1表达的CLL细胞对Venetoclax诱导的亡敏感性降低,并在BCAT1中断时体外生长率降低.
- 在CLL患者中,BCAT1蛋白表达独立地与较短的中位生存期相关 (125个月与296个月).
结论:
- BCAT1在CLL的一个子集中异常表达,特别是那些具有不良遗传特征的人.
- BCAT1影响CLL细胞代谢,mTOR信号传递,以及对亡的抵抗力.
- BCAT1表达是CLL生存时间缩短的显著独立预后标志物,表明其作为治疗点的潜力.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


